Ready-to-go viral vector platform

The exoReady™ viral vector platform integrates our high-performing starting materials (cell lines and vector systems) with our data-driven expertise and comprehensive documentation package, including standard operating procedures, bills of testing, and material specifications. This flexible manufacturing technology, combined with our CMC package, offers a complete solution to support the production of viral vector-based vaccines, oncolytic therapies, and gene therapy products

Ready-to-go viral vector technology platform

exoREADY is a viral vector technology platform providing an off-the-shelf solution for transient expression for both adeno-associated virus (AAV) and lentivirus (LV) compatible with adherent and suspension culture based on a HEK-293 cell line. The platform also provides pre-optimized downstream purification processes, a development analytical toolkit and dedicated in-process and release quality control methods that can address all the steps required for the manufacture of complex advanced therapies in a fast, efficient, and lower cost manner.

Capitalize on exoREADY technology platform

Viral vector 

dedicated platform

  • EProprietary manufacturing platform
  • EDedicated to industrial manufacturing of viral vectors for Cell and Gene Therapy & Vaccine
  • EFully customizable

Ready to use 

technology

  • EState-of-the-art USP equipment
  • EState-of-the-art DSP equipment
  • EPre-developed analytical toolkit
  • ECMC and regulatory support

Capitalize on exoREADY technology platform

Viral vector dedicated platform

  • EProprietary technology platform
  • EDedicated to industrial manufacturing of viral vectors for Cell and Gene Therapy
  • EFully customizable
  • EHEK293 cell bank

scale-X™ bioreactor leader

  • ENew industry gold standard
  • EOne of the most experienced CDMOs
  • ECompleted runs at Exothera: 60+

Ready to use technology

  • EState-of-the-art USP equipment
  • EState-of-the-art DSP equipment
  • EPre-developed analytical toolkit
  • ECMC and regulatory support

Get faster to the clinical phase without quality compromise

We work day by day to reduce the development timeline without compromising on quality and costs. 

Viral vectors technology platform and evolution exoready clinical phase timeline comparison

Get faster to the clinical phase without quality compromise

We work day by day to reduce the development timeline without compromising on quality and costs.

Viral vectors technology platform and evolution exoready clinical phase timeline comparison

Bring manufacturing process to GMP

Developed for both adherent and suspension cell culture and equipped with the latest DSP technologies.  

Scalable suspension-based process

  • Manufacturing scale : 40L – 200L – 2000L in Stirred Tank bioreactor
  • Proven robust and agile scalability
  • Simple tech transfer to client’s facility
  • Scale-down model for process characterization and optimization
  • Continuous processing/perfusion with ATF system
  • Compatible with serum-free and chemically defined media

Scalable adherent-based process

  • Manufacturing scale : 10 m² – 30 m² – 200 m² – 600 m²  in Fixed bed bioreactor  (scale-X™)
  • Robust, consistent, monitored and fast transfer from flatware processes to  GMP environment
  • High cell density per footprint – Applicable for adherent and suspension cell lines
  • The fixed-bed architecture acts as a pre-filter, easing the perfusion management without additional devices or equipment
  • Integrated solution chained processes as in-line clarification and TFF

For any questions

Please contact us and we will respond quickly!  

For any questions

Please contact us and we will respond quickly!